Schizophrenia  - Market Insights, Epidemiology and Market Forecast 2027

Schizophrenia - Market Insights, Epidemiology and Market Forecast 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2018
  • SKU: DIMI0338
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Corporate License
    ()
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Schizophrenia  - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Schizophrenia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Schizophrenia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027
Schizophrenia - Disease Understanding and Treatment Algorithm
According to National Institute of Mental Health, Schizophrenia is a chronic and severe mental disorder characterized by profound disruptions in thought processes, perceptions, emotional responsiveness and social interactions. It can impair functioning through the loss of an acquired capability to earn a livelihood, or the disruption of studies. The symptoms includes hallucinations, delusions and thought disorder (unusual ways of thinking), as well as reduced expression of emotions, reduced motivation to accomplish goals, motor impairment and cognitive impairment. It typically begins in late adolescence or early adulthood.
The DelveInsight Schizophrenia market report gives the thorough understanding of the Schizophrenia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Schizophrenia in the US, Europe, and Japan.

Schizophrenia Epidemiology
The Schizophrenia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Case, Incident Cases, Diagnosed Prevalence, Gender Specific Prevalence, and Age Specific Prevalence] scenario of Schizophrenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to World Health Organization (WHO), the data from European and North American studies show persisting disability of moderate or severe degree in about 40% of males with schizophrenia, in contrast with 25% of females
 
Schizophrenia Drug Chapters
This segment of the Schizophrenia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The major marketed drugs approved for Schizophrenia are based on dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Rexulti (Otsuka Pharmaceutical), Seroquel (AstraZeneca) and Invega Sustenna (Janssen Pharmaceuticals) are the drugs used for the treatment of patients with Schizophrenia. Most currently approved therapies for schizophrenia are primarily directed toward positive symptoms.

Schizophrenia Market Outlook
The Schizophrenia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Key players such as Sunovion, H. Lundbeck A/S, Minerva Neurosciences, and many others are involved in developing therapies for Schizophrenia. Expected launch of emerging therapies such as SEP-363856 (Sunovion), Lu AF35700 (H. Lundbeck A/S), Roluperidone (Minerva Neurosciences), and other compelling therapies are expected to increase the market size of Schizophrenia in upcoming years.

Schizophrenia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Schizophrenia Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Schizophrenia Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Schizophrenia Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Schizophrenia market

• Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia market

• To understand the future market competition in the Schizophrenia market.

1. Report Introduction
2. Schizophrenia  Market Overview at a Glance
2.1. 7 Major Market Size (%) of Schizophrenia  in 2017
2.2. 7 Major Market Size (%) of Schizophrenia  in 2027
3. Disease Background and Overview: Schizophrenia   
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
4. Diagnosis
5. Epidemiology and Patient Population
5.1. 7MM Incident Cases of Schizophrenia (2016-2027)
5.2. 7MM Prevalent Cases of Schizophrenia (2016-2027)
5.3. 7MM Diagnosed Cases of Schizophrenia (2016-2027)
5.4. 7MM Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
5.5. 7MM Gender Specific Prevalent  Cases of Schizophrenia (2016-2027)
6. Schizophrenia : Country- Wise Epidemiology
6.1. United States
6.1.1. Incident Cases of Schizophrenia (2016-2027)
6.1.2. Prevalent Cases of Schizophrenia (2016-2027)
6.1.3. Diagnosed Cases of Schizophrenia (2016-2027)
6.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
6.2. EU-5
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1.1. Incident Cases of Schizophrenia (2016-2027)
6.3.1.2. Prevalent Cases of Schizophrenia  (2016-2027)
6.3.1.3. Diagnosed Cases of Schizophrenia (2016-2027)
6.3.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.3.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
6.4. France
6.4.1.1. Incident Cases of Schizophrenia (2016-2027)
6.4.1.2. Prevalent Cases of Schizophrenia (2016-2027)
6.4.1.3. Diagnosed Cases of Schizophrenia (2016-2027)
6.4.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.4.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
6.5. Italy
6.5.1.1. Incident Cases of Schizophrenia (2016-2027) 
6.5.1.2. Prevalent Cases of Schizophrenia  (2016-2027)
6.5.1.3. Diagnosed Cases of Schizophrenia (2016-2027)
6.5.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.5.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
6.6. Spain
6.6.1.1. Incident Cases of Schizophrenia (2016-2027) 
6.6.1.2. Prevalent Cases of Schizophrenia  (2016-2027)
6.6.1.3. Diagnosed Cases of Schizophrenia (2016-2027) 
6.6.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.6.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
6.7. United Kingdom
6.7.1.1. Incident Cases of Schizophrenia (2016-2027) 
6.7.1.2. Prevalent Cases of Schizophrenia (2016-2027) 
6.7.1.3. Diagnosed Cases of Schizophrenia  (2016-2027)
6.7.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.7.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
6.8. Japan
6.8.1.1. Incident Cases of Schizophrenia (2016-2027) 
6.8.1.2. Prevalent Cases of Schizophrenia (2016-2027) 
6.8.1.3. Diagnosed Cases of Schizophrenia (2016-2027) 
6.8.1.4. Age-Specific Prevalent Cases of Schizophrenia (2016-2027)
6.8.1.5. Gender Specific Prevalent Cases of Schizophrenia (2016-2027)
7. Treatments & Medical Practices
7.1. Treatment Algorithm
7.2. Treatment Guidelines
8. Marketed Products
8.1. Rexulti : Otsuka Pharmaceutical
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages and Disadvantages
8.1.5. Safety and Efficacy
8.1.6. Product Profile
8.2. Seroquel: AstraZeneca
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages and Disadvantages
8.2.5. Safety and Efficacy
8.2.6. Product Profile
8.3. Invega Sustenna: Janssen Pharmaceuticals
8.3.1. Drug Description
8.3.2. Mechanism of Action
8.3.3. Regulatory Milestones
8.3.4. Advantages and Disadvantages 
8.3.5. Safety and Efficacy
8.3.6. Product Profile
To be continued in report…
9. Emerging Therapies
9.1. Key Cross Competition
9.2. SEP-363856: Sunovion
9.2.1. Regulatory Milestones
9.2.2. Clinical Development
9.2.3. Product Profile
9.2.4. Clinical Pipeline Activity
9.2.4.1. Ongoing Trials Information
9.2.4.2. Clinical Trial by Phase
9.3. Lu AF35700: H. Lundbeck A/S
9.3.1.  Regulatory Milestones
9.3.2.  Clinical Development
9.3.3.  Product Profile
9.3.4.  Clinical Pipeline Activity
9.3.4.1. Ongoing Trials Information
9.3.4.2. Clinical Trial by Phase
9.4. Roluperidone: Minerva Neurosciences
9.4.1. Regulatory Milestones
9.4.2.  Clinical Development
9.4.3.  Product Profile
9.4.4.  Clinical Pipeline Activity
9.4.4.1. Ongoing Trials Information
9.4.4.2. Clinical Trial by Phase
To be continued in report…
10. Schizophrenia  Market Size
10.1. Key Findings
10.2. Total 7MM Schizophrenia Market Analysis 
10.2.1. Overview of Total Schizophrenia  Market 
10.2.2.  Market size of Schizophrenia Market by 7MM (2016-2027)
11. 7MM: Country-Wise Market Analysis
11.1. United States Market Size
11.1.1. Total Market Size of Schizophrenia  
11.1.2. Market Size of Schizophrenia by Therapies
11.2. Germany Market Size
11.2.1. Total Market Size of Schizophrenia  
11.2.2. Market Size of Schizophrenia by Therapies
11.3. France Market Size
11.3.1. Total Market Size of Schizophrenia  
11.3.2. Market Size of Schizophrenia by Therapies
11.4. United Kingdom Market Size
11.4.1. Total Market Size of Schizophrenia  
11.4.2. Market Size of Schizophrenia by Therapies
11.5. Spain Market Size
11.5.1. Total Market Size of Schizophrenia  
11.5.2. Market Size of Schizophrenia by Therapies
11.6. Italy Market Size
11.6.1. Total Market Size of Schizophrenia  
11.6.2. Market Size of Schizophrenia by Therapies
11.7. Japan Market Size
11.7.1. Total Market Size of Schizophrenia  
11.7.2. Market Size of Schizophrenia by Therapies
12. Market Drivers
13. Market Barriers
14. Report Methodology
14.1. Sources Used
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Table 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Table 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Table 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Table 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Table 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Table 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Table 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Table 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Table 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Table 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Table 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Table 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Table 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Table 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Table 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Table 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Table 26 Incident Cases of Schizophrenia in France (2016-2027)
Table 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Table 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Table 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Table 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Table 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Table 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Table 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Table 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Table 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Table 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Table 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Table 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Table 42 SEP-363856, Clinical Trials by Zone, 2018
Table 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Table 44 Lu AF35700, Clinical Trials by Zone, 2018
Table 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Table 46 Roluperidone , Clinical Trials by Zone, 2018
Table 47 Total 7 Major Market Size in USD, Million (2016-2027)
Table 48 Region wise Market Size) in USD, Million (2016-2027)
Table 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 50 United States Market Size in USD, Million (2016-2027)
Table 51 United States Market Size by Therapy in USD, Million (2016-2027)
Table 52 Germany  Market Size in USD, Million (2016-2027)
Table 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 54 France  Market Size in USD, Million (2016-2027)
Table 55 France Market Size by Therapy in USD, Million (2016-2027)
Table 56 United Kingdom  Market Size in USD, Million (2016-2027)
Table 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 58 Spain Market Size in USD, Million (2016-2027)
Table 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 60 Italy Market Size in USD, Million (2016-2027)
Table 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 62 Japan Market Size in USD, Million (2016-2027)
Table 63 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Figure 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Figure 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Figure 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Figure 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Figure 6 Incident Cases of Schizophrenia  in the United States (2016-2027)
Figure 7 Prevalent Cases of Schizophrenia  in the United States (2016-2027)
Figure 8 Diagnosed Cases of Schizophrenia  in the United States (2016-2027)
Figure 9 Age-Specific Prevalent Cases of Schizophrenia in the United States (2016-2027)
Figure 10 Gender Specific prevalent cases of Schizophrenia in the United States (2016-2027)
Figure 11 Incident Cases of Schizophrenia in Germany (2016-2027)
Figure 12 Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 13 Diagnosed Cases of Schizophrenia in Germany (2016-2027)
Figure 14 Age-Specific Prevalent Cases of Schizophrenia in Germany (2016-2027)
Figure 15 Gender Specific prevalent cases of Schizophrenia in Germany (2016-2027)
Figure 16 Incident Cases of Schizophrenia in Italy (2016-2027)
Figure 17 Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 18 Diagnosed Cases of Schizophrenia in Italy (2016-2027)
Figure 19 Age-Specific Prevalent Cases of Schizophrenia in Italy (2016-2027)
Figure 20 Gender Specific prevalent cases of Schizophrenia in Italy (2016-2027)
Figure 21 Incident Cases of Schizophrenia in Spain (2016-2027)
Figure 22 Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 23 Diagnosed Cases of Schizophrenia in Spain (2016-2027)
Figure 24 Age-Specific Prevalent Cases of Schizophrenia in Spain (2016-2027)
Figure 25 Gender Specific prevalent cases of Schizophrenia in Spain (2016-2027)
Figure 26 Incident Cases of Schizophrenia in France (2016-2027)
Figure 27 Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 28 Diagnosed Cases of Schizophrenia in France (2016-2027)
Figure 29 Age-Specific Prevalent Cases of Schizophrenia in France (2016-2027)
Figure 30 Gender Specific prevalent cases of Schizophrenia in France (2016-2027)
Figure 31 Incident Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 32 Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 33 Diagnosed Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 34 Age-Specific Prevalent Cases of Schizophrenia in the United Kingdom (2016-2027)
Figure 35 Gender Specific prevalent cases of Schizophrenia in the United Kingdom(2016-2027)
Figure 36 Incident Cases of Schizophrenia in Japan(2016-2027)
Figure 37 Prevalent Cases of Schizophrenia in Japan(2016-2027)
Figure 38 Diagnosed Cases of Schizophrenia in Japan(2016-2027)
Figure 39 Age-Specific Prevalent Cases of Schizophrenia in Japan (2016-2027)
Figure 40 Gender Specific prevalent cases of Schizophrenia in Japan (2016-2027)
Figure 41 SEP-363856, Clinical Trials by Recruitment status, 2018
Figure 42 SEP-363856, Clinical Trials by Zone, 2018
Figure 43 Lu AF35700, Clinical Trials by Recruitment status, 2018
Figure 44 Lu AF35700, Clinical Trials by Zone, 2018
Figure 45 Roluperidone, Clinical Trials by Recruitment status, 2018
Figure 46 Roluperidone , Clinical Trials by Zone, 2018
Figure 47 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 48 Region wise Market Size) in USD, Million (2016-2027)
Figure 49 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United States Market Size in USD, Million (2016-2027)
Figure 51 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Germany  Market Size in USD, Million (2016-2027)
Figure 53 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 54 France  Market Size in USD, Million (2016-2027)
Figure 55 France Market Size by Therapy in USD, Million (2016-2027)
Figure 56 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 57 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 58 Spain Market Size in USD, Million (2016-2027)
Figure 59 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 60 Italy Market Size in USD, Million (2016-2027)
Figure 61 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 62 Japan Market Size in USD, Million (2016-2027)
Figure 63 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 64 Market Drivers
Figure 65 Market Barriers

 

Table 1 Incident Cases of Schizophrenia  in 7MM (2016-2027)
Table 2 Prevalent Cases of Schizophrenia  in 7MM (2016-2027)
Table 3 Diagnosed Cases of Schizophrenia  in 7MM (2016-2027)
Table 4 Age-Specific Prevalent Cases of Schizophrenia in 7MM (2016-2027)
Table 5 Gender Specific prevalent cases of Schizophrenia in 7MM (2016-2027)
Table 6 Incident Cases of Schizophrenia  in the United States